JSPR · Jasper Therapeutics

Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. Its products in various stages of development include KP-104, a dual-complement inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) which is in Phase 2; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders. The company is headquartered in Redwood City, California.

2200 Bridge Pkwy, Redwood City, CA, 94065, United States
Biotechnology
Healthcare

Market Cap

11.48M

52 Wk Range

$9.25 - $72.60

Previous Close

$10.34

Open

$10.67

Volume

19,298

Day Range

$10.66 - $11.86

Enterprise Value

6.354M

Cash

135.3M

Avg Qtr Burn

-5.497M

Insider Ownership

2.55%

Institutional Own.

56.46%

Qtr Updated

Sep 30th 2026